surmount-1 tirzepatide non-diabetic obesity trial Effect of in trial. (BMI: body mass index; CI: surmount-1 trial tirzepatide weight loss
Description
thereafter, 5 mg each week) to attempt to improve poor glycemic control
Semaglutide mimics GLP-1 activity
All medications within these trials are once weekly subcutaneously-administered injections
There is no room for interpretation here
The tirzepatide for weight loss guide details the expected outcomes at each dose tier based on the SURMOUNT trial data
This creates prolonged fullness after meals
